Kathryn E Falberg - Net Worth and Insider Trading

Kathryn E Falberg Net Worth

The estimated net worth of Kathryn E Falberg is at least $56 Million dollars as of 2024-04-25. Kathryn E Falberg is the Director of The Trade Desk Inc and owns about 292,609 shares of The Trade Desk Inc (TTD) stock worth over $24 Million. Kathryn E Falberg is the EVP and CFO of Jazz Pharmaceuticals PLC and owns about 124,721 shares of Jazz Pharmaceuticals PLC (JAZZ) stock worth over $13 Million. Kathryn E Falberg is also the Director of Halozyme Therapeutics Inc and owns about 280,000 shares of Halozyme Therapeutics Inc (HALO) stock worth over $11 Million. Besides these, Kathryn E Falberg also holds Aimmune Therapeutics Inc (AIMT) , Arcus Biosciences Inc (RCUS) , Nuvation Bio Inc (NUVB) , Sio Gene Therapies Inc (SIOX) , ARCA biopharma Inc (ABIO) , Tricida Inc (TCDAQ) . Details can be seen in Kathryn E Falberg's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kathryn E Falberg has not made any transactions after 2024-03-08 and currently still holds the listed stock(s).

Transaction Summary of Kathryn E Falberg

To

Kathryn E Falberg Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kathryn E Falberg owns 14 companies in total, including Aimmune Therapeutics Inc (AIMT) , Tricida Inc (TCDAQ) , and UroGen Pharma Ltd (URGN) among others .

Click here to see the complete history of Kathryn E Falberg’s form 4 insider trades.

Insider Ownership Summary of Kathryn E Falberg

Ticker Comapny Transaction Date Type of Owner
AIMT Aimmune Therapeutics Inc 2020-10-10 director
TCDAQ Tricida Inc 2018-07-02 director
URGN UroGen Pharma Ltd 2019-01-01 director
RCUS Arcus Biosciences Inc 2021-03-31 director
TTD The Trade Desk Inc 2024-03-08 director
SIOX Sio Gene Therapies Inc 2017-04-17 director
MDVN Medivation Inc 2016-09-28 director
BMRN Biomarin Pharmaceutical Inc 2016-07-15 director
LIFE aTyr Pharma Inc 2015-07-08 director
HALO Halozyme Therapeutics Inc 2014-05-13 director
JAZZ Jazz Pharmaceuticals PLC 2014-02-12 SVP and CFO
NVLNF Novelion Therapeutics Inc 2011-05-26 director
ABIO ARCA biopharma Inc 2009-02-23 CFO and COO
NUVB Nuvation Bio Inc 2022-12-05 director

Kathryn E Falberg Latest Holdings Summary

Kathryn E Falberg currently owns a total of 9 stocks. Among these stocks, Kathryn E Falberg owns 292,609 shares of The Trade Desk Inc (TTD) as of March 8, 2024, with a value of $24 Million and a weighting of 43.38%. Kathryn E Falberg owns 124,721 shares of Jazz Pharmaceuticals PLC (JAZZ) as of February 12, 2014, with a value of $13 Million and a weighting of 23.84%. Kathryn E Falberg also owns 280,000 shares of Halozyme Therapeutics Inc (HALO) as of August 14, 2013, with a value of $11 Million and a weighting of 19.16%. The other 6 stocks Aimmune Therapeutics Inc (AIMT) , Arcus Biosciences Inc (RCUS) , Nuvation Bio Inc (NUVB) , Sio Gene Therapies Inc (SIOX) , ARCA biopharma Inc (ABIO) , Tricida Inc (TCDAQ) have a combined weighting of 13.62% among all his current holdings.

Latest Holdings of Kathryn E Falberg

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TTD The Trade Desk Inc 2024-03-08 292,609 83.34 24,386,034
JAZZ Jazz Pharmaceuticals PLC 2014-02-12 124,721 107.43 13,398,777
HALO Halozyme Therapeutics Inc 2013-08-14 280,000 38.46 10,768,800
AIMT Aimmune Therapeutics Inc 2018-02-26 124,894 34.49 4,307,594
RCUS Arcus Biosciences Inc 2021-03-31 182,610 14.73 2,689,845
NUVB Nuvation Bio Inc 2022-12-05 250,000 2.62 655,000
SIOX Sio Gene Therapies Inc 2017-04-17 6,742 0.48 3,223
ABIO ARCA biopharma Inc 2009-02-23 28 3.48 97
TCDAQ Tricida Inc 2018-07-02 35,211 0.00 0

Holding Weightings of Kathryn E Falberg


Kathryn E Falberg Form 4 Trading Tracker

According to the SEC Form 4 filings, Kathryn E Falberg has made a total of 4 transactions in The Trade Desk Inc (TTD) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in The Trade Desk Inc is the sale of 103,030 shares on March 8, 2024, which brought Kathryn E Falberg around $8 Million.

According to the SEC Form 4 filings, Kathryn E Falberg has made a total of 0 transactions in Jazz Pharmaceuticals PLC (JAZZ) over the past 5 years. The most-recent trade in Jazz Pharmaceuticals PLC is the sale of 2,000 shares on February 12, 2014, which brought Kathryn E Falberg around $314,000.

According to the SEC Form 4 filings, Kathryn E Falberg has made a total of 0 transactions in Halozyme Therapeutics Inc (HALO) over the past 5 years. The most-recent trade in Halozyme Therapeutics Inc is the acquisition of 100,000 shares on August 14, 2013, which cost Kathryn E Falberg around $682,000.

More details on Kathryn E Falberg's insider transactions can be found in the Insider Trading History of Kathryn E Falberg table.

Insider Trading History of Kathryn E Falberg

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kathryn E Falberg Trading Performance

GuruFocus tracks the stock performance after each of Kathryn E Falberg's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kathryn E Falberg is 19.34%. GuruFocus also compares Kathryn E Falberg's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kathryn E Falberg within 3 months outperforms 12 times out of 17 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Kathryn E Falberg's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Kathryn E Falberg

Average Return

80.95%

Average return per transaction

Outperforming Transactions

71%

12 out of 17 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.99 19.34 22.6 80.95 44.82 36.67
Relative Return to S&P 500(%) 2.7 14.46 14.97 69.2 33.05 25.24

Kathryn E Falberg Ownership Network

Ownership Network List of Kathryn E Falberg

No Data

Ownership Network Relation of Kathryn E Falberg


Kathryn E Falberg Owned Company Details

What does Aimmune Therapeutics Inc do?

Who are the key executives at Aimmune Therapeutics Inc?

Kathryn E Falberg is the director of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and Chief Medical Officer Adelman Daniel C Md .

Aimmune Therapeutics Inc (AIMT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aimmune Therapeutics Inc Insider Transactions

No Available Data

Kathryn E Falberg Mailing Address

Above is the net worth, insider trading, and ownership report for Kathryn E Falberg. You might contact Kathryn E Falberg via mailing address: C/o Axovant Sciences, Inc., 320 West 37th Street, 5th Floor, New York Ny 10018.

Discussions on Kathryn E Falberg

No discussions yet.